{"nctId":"NCT02819284","briefTitle":"Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease","startDateStruct":{"date":"2016-06","type":"ACTUAL"},"conditions":["Dry Eye Syndromes","Keratoconjunctivitis Sicca"],"count":909,"armGroups":[{"label":"KPI-121 0.25% Ophthalmic Suspension","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: KPI-121 0.25% Ophthalmic Suspension"]},{"label":"Vehicle of KPI-121 0.25% Ophthalmic Suspension","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Vehicle of KPI-121 0.25% Ophthalmic Suspension"]}],"interventions":[{"name":"KPI-121 0.25% Ophthalmic Suspension","otherNames":["Loteprednol etabonate"]},{"name":"Vehicle of KPI-121 0.25% Ophthalmic Suspension","otherNames":["Placebo"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have a documented clinical diagnosis of dry eye disease in both eyes\n\nExclusion Criteria:\n\n* Known hypersensitivity or contraindication to the investigational product(s) or components\n* History of glaucoma, IOP\\>21 mmHg at the screening or randomization visits, or being treated for glaucoma in either eye.\n* Diagnosis of: ongoing ocular infection; severe/serious ocular condition that in judgment of Investigator could confound study assessments or limit compliance; or have been exposed to an investigational drug within 30 days prior to screening.\n* In the opinion of the Investigator or study coordinator, be unwilling or unable to comply with study protocol or unable to successfully instill eye drops.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline/Visit 2 (Day 1) in Bulbar Conjunctival Hyperemia at Visit 4 (Day 15)","description":"Comparison of mean change from baseline for bulbar conjunctival hyperemia in the study eye between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-4 grading scale. The grading scale was based on the Cornea and Contact Lens Research Unit Grading Scale where 0 = none, 1 = very slight, 2 = slight, 3 = moderate and 4 = severe.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3812","spread":"0.60560"},{"groupId":"OG001","value":"-0.2371","spread":"0.62256"}]}]}]},{"type":"PRIMARY","title":"Change From Baseline/Visit 2 (Day 1) in Ocular Discomfort Severity at Visit 4 (Day 15)","description":"Comparison of mean ocular discomfort between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-100 visual analog grading scale where 0 was better and 100 was worse.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.14","spread":"19.901"},{"groupId":"OG001","value":"-9.24","spread":"17.002"}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects With ≥ 1 Unit Improvement From Baseline/Visit 2 (Day 1) in Bulbar Conjunctival Hyperemia Worst Region at Visit 4 (Day 15)","description":"Proportion of subjects with ≥1 improvement from baseline in conjunctival hyperemia scores in the study eye. The grading scale was based on the Cornea and Contact Lens Research Unit Grading Scale where 0 = none, 1 = very slight, 2 = slight, 3 = moderate and 4 = severe.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"171","spread":null},{"groupId":"OG001","value":"127","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline/ Visit 2 (Day 1) in Ocular Discomfort Severity Scores at Visit 3 (Day 8)","description":"Comparison of ocular discomfort scores between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-100 visual analog grading scale where 0 was better and 100 was worse using 3-day mean scores.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.92","spread":"15.541"},{"groupId":"OG001","value":"-4.86","spread":"14.911"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline/Week 2 (Day 1) in Ocular Discomfort Scores to Day 4","description":"Comparison of mean ocular discomfort between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-100 visual analog grading scale where 0 was better and 100 was worse.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.09","spread":"14.523"},{"groupId":"OG001","value":"-4.10","spread":"14.894"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline/Week 2 (Day 1) in Ocular Discomfort Severity at Visit 4 (Day 15) in a Subgroup","description":"Comparison of mean ocular discomfort between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-100 visual analog grading scale where 0 was better and 100 was worse, in a sub-group of participants with more severe ocular discomfort at baseline, using 3 day means.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.45","spread":"20.352"},{"groupId":"OG001","value":"-9.45","spread":"17.489"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline/Visit 2 (Day 1) in Ocular Discomfort Severity Scores at Day 3 (Diary)","description":"Comparison of mean ocular discomfort severity between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-100 visual analog grading scale where 0 was better and 100 was worse.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.28","spread":"13.697"},{"groupId":"OG001","value":"-3.15","spread":"14.126"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline/Visit 2 (Day 1) in Eye Dryness Scores at Visit 4 (Day 15)","description":"Comparison of mean eye dryness between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-100 visual analog grading scale where 0 was better and 100 was worse.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.0","spread":"22.78"},{"groupId":"OG001","value":"-11.5","spread":"20.53"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline/Visit 2 (Day 1) in Eye Dryness Scores at Visit 3 (Day 8)","description":"Comparison of mean eye dryness between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-100 visual analog grading scale where 0 was better and 100 was worse.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.6","spread":"18.66"},{"groupId":"OG001","value":"-8.0","spread":"18.94"}]}]}]},{"type":"SECONDARY","title":"Ocular Discomfort Severity Scores on Day 2 (Diary) Minus Baseline/Visit 2 (Day 1)","description":"Comparison of mean ocular discomfort between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-100 visual analog grading scale where 0 was better and 100 was worse.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.33","spread":"13.707"},{"groupId":"OG001","value":"-2.43","spread":"13.364"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline/Visit 2 (Day 1) in Ocular Discomfort Frequency Scores at Visit 4 (Day 15)","description":"Comparison of mean ocular discomfort frequency between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-100 visual analog grading scale where 0 was better and 100 was worse.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.20","spread":"20.722"},{"groupId":"OG001","value":"-8.38","spread":"17.974"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline/Visit 2 (Day 1) in Subject-rated Ocular Discomfort Frequency Scores at Visit 3 (Day 8)","description":"Comparison of mean ocular discomfort frequency between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using a 0-100 visual analog grading scale where 0 was better and 100 was worse.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.96","spread":"16.133"},{"groupId":"OG001","value":"-4.42","spread":"16.133"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline/Visit 2 (Day 1) in Inferior Corneal Fluorescein Staining Score at Visit 4 (Day 15)","description":"Comparison of mean corneal fluorescein staining in the study eye between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using methods developed by the National Eye Institute (NEI) Dry Eye Workshop in evaluating 5 regions of the cornea (superior, inferior, nasal, temporal and central) using a 0-3 grading scale, where 0 = no visible staining, 1 = Mild, 2 = moderate and 3 = severe.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"0.86"},{"groupId":"OG001","value":"-0.5","spread":"0.83"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline/Visit 2 (Day 1) in Nasal Corneal Fluorescein Staining Score at Visit 4 (Day 15)","description":"Comparison of mean nasal corneal fluorescein staining in the study eye between the KPI-121 0.25% ophthalmic suspension group and the vehicle group using methods developed by the National Eye Institute (NEI) Dry Eye Workshop in evaluating 5 regions of the cornea (superior, inferior, nasal, temporal and central) using a 0-3 grading scale, where 0 = no visible staining, 1 = Mild, 2 = moderate and 3 = severe.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"0.86"},{"groupId":"OG001","value":"-0.4","spread":"0.83"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":452},"commonTop":["Instillation site pain","Eye pruritus","Vision blurred","Eye irritation","Conjunctival hyperaemia"]}}}